Physician profile
Danielle Duffy
NPI 1104570308
$2,364.54
in general payments reported to CMS, 2019-2025
20 companies · $1,622 in 2025
The $1,622 reported for 2025 was more than what 91% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $153 · 2024: $589 · 2025: $1,622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,364.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $384.64 | 2024-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $326.81 | 2023-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $304.99 | 2023-2025 | |
| Novo Nordisk INC | $182.54 | 2024-2025 | Ozempic, Rybelsus |
| Atricure, INC. | $175.08 | 2025 | Atriclip Laa Exclusion System, Atricure Cryoice Cryoablation System (Cryo2) |
| Medtronic, INC. | $163.52 | 2025 | Corevalve Evolut R |
| Janssen Pharmaceuticals, INC | $160.40 | 2024 | Xarelto |
| Pfizer INC. | $136.77 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $105.59 | 2023-2025 | Farxiga, Wainua |
| Amgen INC. | $94.01 | 2024-2025 | Repatha, Repatha |
| Scpharmaceuticals INC. | $93.85 | 2024-2025 | |
| Edwards Lifesciences Corporation | $54.26 | 2025 | Sapien 3 Ultra Resilia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.69 | 2024 | Jardiance |
| Cvrx, INC. | $27.42 | 2024 | Barostim Neo System |
| Lilly USA, LLC | $25.74 | 2025 | Mounjaro |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.04 | 2023 | Lifevest |
| Abbvie INC. | $20.17 | 2023 | |
| Esperion Therapeutics, INC. | $18.16 | 2025 | Nexletol |
| Altathera Pharmaceuticals LLC | $16.56 | 2025 | Sotalol Hydrochloride |
| Heartflow, INC. | $15.30 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Duffy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.